MR contrast developer Epix Medical will begin development of a molecularly-targeted imaging agent designed to detect thrombus in humans using MRI. The compound, called EP-2104R, is expected to enter human trials in 2004, according to the Cambridge, MA-based firm.
By AuntMinnie.com staff writersApril 1, 2003
Related Reading
Epix contrast agent clears second phase III trial, March 8, 2003
Epix testing of MS-325 moves forward, February 4, 2003
Epix losses continue, MS-325 enrollment completed, October 25, 2002
Epix net loss widens, delays MS-325 NDA, July 26, 2002
Epix shows first-quarter loss, April 24, 2002
Copyright © 2003 AuntMinnie.com